News

New members bring a wealth of experience and expertise from various sectors within the ophthalmology, pharmaceutical, and healthcare fields, further strengthening the Ophthalmology Foundation's mission.

Wang and colleagues conducted a retrospective case series patients with full-thickness macular holes.

Research estimates that the RVO market with see a compound annual growth rate of 11.9%.

With 37 years of clinical trial experience, Peter J. McDonnell, MD, offer some tips.

The investigators explained that the survival rate of patients with retinoblastoma has improved significantly as a result of intra-arterial chemotherapy and enucleation surgery.

After 3 loading doses, the patients were randomly assigned to receive EYP-1901 or continue to receive aflibercept at an 8-week dosing pattern for 32 weeks.

A review of the phase 4 PALADIN data show that steroid-eluting implants lead to good vision, safe outcomes, and reduced burden in patients with DME.

An investigation is set to launch on SpaceX’s 30th Commercial Resupply Services mission to the International Space Station contracted by NASA to test the therapy in space.

Gildeuretinol halts Stargardt disease progression for up to 6 years.

Andrew G. Lee, MD, outlines his stance on whether all patients with idiopathic intracranial hypertension should have a lumbar puncture, emphasizing clinical judgment and treatment strategies.

The International Headache Society has provided criteria for visual snow syndrome (VSS).

Observing potential cases highlights the importance of monitoring and reporting, contributing to a comprehensive understanding of therapeutic effects.

Retina specialists Giuseppe Querques, MD, PhD, and Paolo Lanzetta, MD, debate at the Congress on Controversies in Ophthalmology

The good news for patients is that GA is transitioning from an untreatable disease to a potentially treatable one with development of new therapies to reduce the growth rate, and use of anti-complement therapies have caused the growth rate of GA lesions to decrease.

Ophthalmologists can educate their patients about the importance of using certified solar viewing glasses or other safe viewing methods.

When we discuss trial participation with patients, we stress that the goal of these studies is to obtain better visual outcomes and ease the treatment burden.

At this year's Congress on Controversies in Ophthalmology, keynote speaker Ursula Schmidt-Erfurth, MD, addressed the clinical use of artificial intelligence

OCU410 is a modifier gene therapy candidate being developed for geographic atrophy, an advanced stage of dry age related macular degeneration.

The collaboration combines Clario's transformative technology with Cleveland Clinic's market-leading imaging expertise and AI-enabled analysis to help bring new therapies to patients, faster.

The trial evaluated nesvategrast (OTT166 5%) eye drops in patients with diabetic retinopathy.

Advances in virtual reality and AI are helping those with AMD and low vision.

Research indicates smoking increases risk of AMD, cataracts and glaucoma

Ferrone’s role will be effective as of March 18, 2024.

In the study, published in Nature Biotechnology, researchers used their new system to correct disease-causing mutations in the eyes of two mouse models of genetic blindness, partially restoring their vision.

Results show Eylea HD extended dosing regimens were non-inferior to aflibercept 2 mg injection (Eylea) for both the treatment of wet age-related macular degeneration (wAMD) and diabetic macular edema (DME).

The study showed that a 12-day treatment of KIO-101 topically at multiple doses was well tolerated in healthy volunteers and patients with inflammation of the eye.